Briumvi (ublituximab-xiiy), is a biologic infusion used to treat relapsing forms of multiple sclerosis (MS), an autoimmune disease that predominantly affects the brain and spinal column.

In people with MS, their own immune system (B-lymphocytes) attack the myelin sheath, which is the protective covering on nerve cells in the central nervous system. When these B-cells are being produced, they have a CD20 marker which helps to identify them.

As the myelin sheath erodes, nerve cells become damaged, preventing them from communicating and sending signals to each other. Over time, this can affect motor skills, speech, bowel function, balance, and vision.

Briumvi is not a cure for MS, however, it is able to target the CD20 marker on B lymphocytes to destroy them so they can no longer harm the nerve cells. This is a way of suppressing the body’s overactive immune response.